IsoRay Announces First International Orders for GliaSite Radiation Therapy System

Wed Jul 11, 2012 7:53am EDT

* Reuters is not responsible for the content in this press release.

  RICHLAND, WA, Jul 11 (Marketwire) -- 
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR), a medical technology
company and innovator in seed brachytherapy and medical radioisotope
applications, today announced another step forward in international
adoption of its ground-breaking GliaSite(R) radiation therapy system, the
world's only liquid radiation balloon catheter device used in the
treatment of brain cancers. IsoRay shipped its first orders to Germany as
mounting inquiries continue to grow Company confidence in the
international market. According to IsoRay CEO Dwight Babcock, "The
medical community is clearly becoming aware of the innovative alternative
that GliaSite(R) presents as an important advance over previous brain
cancer treatments. We are seeing a growth in inquiries from Germany,
Italy, Austria, Switzerland, and the United Kingdom." 

    The GliaSite(R) radiation therapy system gives physicians the ability to
directly place a specified dosage of liquid radiation in areas where
cancer is most likely to remain after completion of brain tumor removal.
The ability to precisely place a specified dosage of this form of
radiation means there is less likelihood for damage to occur to healthy
brain tissue compared to other alternative treatments. GliaSite(R)
diminishes the ability of the tumor to recur, which means important
benefits for patients in longevity as well as quality of life. 

    Babcock says that physicians from the international medical community are
also inquiring about IsoRay's Cesium-131 (Cs-131) seed sutured mesh for
the treatment of a wide array of cancers throughout the body including
brain and lung cancers. Babcock says exceptional results are driving
interest, "The outstanding results that have been realized in treating
such a wide array of cancers throughout the body has doctors expressing
an interest in exploring the use of Cesium-131. These medical thought
leaders recognize the important need for a powerful new weapon in the
battle against cancer." 

    IsoRay has achieved another international milestone with the completion
of the annual ISO 13485:2003 audit from BSI (British Standards
Institution) with no nonconformities. The successful outcome of the audit
means that IsoRay has met or exceeded international standards of
manufacturing and quality systems that allows the Company to continue to
develop the marketability of IsoRay products in Canada and Europe. 

    IsoRay is the exclusive manufacturer of Cesium-131. The pioneering
brachytherapy therapy is one of the most significant advances in internal
radiation therapy in 20 years. Cesium-131 allows for the precise
treatment of many different cancers because of its unrivaled blend of
high energy and its 9.7 day half-life (its unequaled speed in giving off
therapeutic radiation). 

    In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE
mark for international sales in seed form for the treatment of brain
cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal
cancer, gynecologic cancer, head and neck cancer and other cancers
throughout the body. The treatment can be deployed using several delivery
methods including single seed applicators, implantable strands and seed
sutured mesh, and several new implantable devices including the
GliaSite(R) radiation therapy system. 

    About IsoRay 
 IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc.
is the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more about
this innovative Richland, Washington company and explore the many
benefits and uses of GliaSite(R) and Cesium-131 by visiting
www.isoray.com. Join us on Facebook.com/Isoray. Follow us on Twitter
@Isoray.

    Safe Harbor Statement
 Statements in this news release about IsoRay's
future expectations, including: the advantages of our Cesium-131 seed,
the advantages of the Gliasite delivery system, whether IsoRay will be
able to continue to expand its base beyond prostate cancer, whether the
use of GliaSite(R) or Cesium-131 internationally will increase or
continue, and all other statements in this release, other than historical
facts, are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is
included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is important
to note that actual results and ultimate corporate actions could differ
materially from those in such forward-looking statements based on such
factors as physician acceptance, training and use of our products, our
ability to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to meet
demand within required delivery time periods while meeting our quality
control standards, our ability to enforce our intellectual property
rights, whether additional studies are released and support the
conclusions of early clinical studies, patient results achieved with
Cesium-131 or the Gliasite(R) delivery system, successful completion of
future research and development activities, our ability to receive and
maintain all required regulatory approvals in the U.S. and
internationally, continued compliance with ISO standards as audited by
BSI, and other risks detailed from time to time in IsoRay's reports filed
with the SEC. 

    

Contact:
Sharon Schultz
(301) 351-0109
schultzpr@mchsi.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.